Drug Profile
Cannabidiol - GW Pharmaceuticals
Alternative Names: CBD - GW Pharmaceuticals; Epidiolex; Epidiolex/Epidyolex; Epidyolex; GW-42003; GWP-42003; GWP-42003-PLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator GW Pharmaceuticals
- Developer GW Pharmaceuticals; Jazz Pharmaceuticals Inc; University of Alabama at Birmingham; University of Utah
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Antioxidants; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dravet syndrome; Lennox-Gastaut syndrome; Tuberous sclerosis
- Phase III Epilepsy; Infantile spasms; Rett syndrome
- Phase II/III Blepharospasm
- Phase II Heroin-related disorders; Opioid-related disorders; Parkinson's disease; Pervasive child development disorders; Sturge-Weber syndrome
- No development reported Cerebral ischaemia; Duchenne muscular dystrophy; Ovarian cancer
- Discontinued Dyslipidaemias; Myoclonic epilepsies; Non-alcoholic fatty liver disease; Schizophrenia; Type 2 diabetes mellitus; Ulcerative colitis
Most Recent Events
- 08 Mar 2024 Jazz Pharmaceuticals has multiple patent protection for 'the use of CBD in the treatment of epileptic encephalopathies' in the US (Jazz Pharmaceuticals SEC filing, Form 10-K, March 2024)
- 29 Feb 2024 Jazz Pharmaceuticals completes a phase-II clinical trials in Pervasive child development disorders (In adolescents, In children) in United Kingdom, Spain, Germany, Canada, Australia, USA (PO) (NCT04745026) (EudraCT2020-002819-21)
- 23 Feb 2024 Jazz Pharmaceuticals plans a phase II CANAX trial for Fragile X syndrome (In Children, In adolescent, In adults) (PO,Solution) in April 2024 (NCT06261502)